
    study was terminated for business reasons; not due to safety or efficacy concerns.
  
["crohn's disease"]
['brazikumab iv infusion', 'brazikumab sc injection', 'placebo']

        Inclusion Criteria:

          -  Diagnosis of ileal, ileo-colonic, or colonic Crohn's Disease (CD) for > 3 months prior
             to screening

          -  Men or women age 18 - 80 years at the time of screening

          -  Moderate to severely active CD, as defined by Crohn's Disease Activity Index (CDAI)
             and endoscopic demonstration of inflammation

          -  Stable dose of medications for Crohn's disease therapy

          -  Prior treatment failure or intolerance with at least one Anti-Tumor Necrosis
             Factor-Alpha Therapy (anti-TNF α) agent

          -  Effective contraception from screening, and for 36 weeks after the last dose of
             investigational product

          -  No known history of active tuberculosis (TB) & negative assessment for TB/latent TB

        Exclusion Criteria:

          -  Severe underlying immunosuppression

          -  Severe gastrointestinal complications; e.g., short bowel syndromes, obstructing
             strictures, recent or planned bowel surgery, Ileostomy and/or colostomy, recent bowel
             perforation

          -  Significant infections at screening; Infected abscess, positive for Clostridium
             difficile, recent infectious hospitalization

          -  Recent treatment with approved or investigational biologic therapy for Crohn's disease

          -  Recent or planned live attenuated vaccine

          -  History of cancer, except for basal cell carcinoma or carcinoma in situ (CIS) of the
             cervix with apparent cure ≥ 12 months before screening

          -  Pregnancy/breast feeding

          -  Drug abuse
      